Immune checkpoint proteins are key regulators of the immune system and drug targets of cancer immunotherapy. Immune checkpoint molecules have been found on the cell surface of immune cells and tumor cells as activating receptors or inhibitory receptors. Immune checkpoint inhibitors, such as blocking antibodies to cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1) and programmed cell death ligand 1 (PD-L1), have demonstrated significant efficacy in the treatment of a variety of cancers. Recent studies have also shown many immune checkpoint proteins can undergo alternative splicing or proteolytic cleavage to produce soluble checkpoint proteins. The expression levels of soluble and cell-surface immune checkpoint proteins in the circulation and in tumor-microenvironment (TME) may be used as putative immune-based biomarkers for cancer research and biomarker discovery in immunological diseases. MILLIPLEX® Mouse Immuno-Oncology Checkpoint Protein Panel 1 is a 28-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma, cell culture supernatant, cell lysate, and tissue/tumor extract samples: 4-1BBL/TNFSF9, 5′-NT/CD73, B7-H2/ICOSL, B7-H3/CD276, BCA-1/CXCL-13, BTLA, CD137/4-1BB, CD226/DNAM-1, CD25/IL-2Rα, CD27, CD40, CD80/B7-1, CTLA-4/CD152, E-cadherin, Galectin-1, Galectin-3, GITR, Granzyme B, HVEM, IFNγ, IL-10, LAG-3, PD-1, PD-L1, PD-L2, TIM-3, TLR-2, and TNFα. Panel Type: MAGNETIC Circulating Cancer
| 储存条件 |
|
| 象形图 |
|
| 警示语 |
|
| Class |
|
| 警告声明 |
|
| UNub |
|
| 危险声明 |
|
| Packing Group |
|
微信公众号
